These models mimic many of the key aspects of post-TMZ GBM in patients, including C>T transition enrichment, DNA MMR mutations (especially in MSH6), increased TMB, and TMZ resistance, that have been reported in other experimental and patient-based studies [10,11,12,13,14,16,45]. The gene discussed is MSH6; the disease is glioblastoma.